Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.72 |
| ▸ | LTK | P29376 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.72 |
| ▸ | FLT3 | P36888 | 1/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.72 |
| ▸ | PRKX | P51817 | 1/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.72 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.72 |
| ▸ | MST1R | Q04912 | 1/20 | 0.72 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.72 |
| ▸ | BTK | Q06187 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259689 | 1.00 | PLK4 (0.72) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL30809709 | 0.85 | PLK4 (0.58) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL29696521 | 0.84 | PLK4 (1.00) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL20616534 | 0.84 | PLK4 (0.70) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL2264295 | 0.84 | PLK4 (1.00) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL3386425 | 0.84 | PLK4 (0.70) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Oxalic Acid SCHEMBL28217953 | 0.83 | PLK4 (0.90) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| Lithium Ion SCHEMBL30135624 | 0.82 | PLK4 (0.68) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL24992498 | 0.82 | PLK4 (0.62) | PLK4CHEK1AURKADAPK3MAP4K4 | |
| SCHEMBL10593966 | 0.82 | DAPK3 (0.54) | PLK4CHEK1AURKADAPK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | claimed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4561562-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025017711-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NIRAPARIB TOSYLATE MONOHYDRATE | NATCO PHARMA LIMITED (IN) | 2025-01-23 | — | — | WO | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024026128-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-13 | — | — | US | disclosed |
| WO-2022257961-A1 | BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022257960-A1 | BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES | 武汉人福创新药物研发中心有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-115448882-A | Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases | 武汉人福创新药物研发中心有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | PLK4 185/4885CHEK1 179/4885AURKA 389/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | PLK4 185/4885CHEK1 179/4885AURKA 389/4885 |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-20230110576-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-11312712-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-20230114165-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | PLK4 2558/4885CHEK1 3206/4885AURKA 744/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | PLK4 2546/4885CHEK1 3252/4885AURKA 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.